Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201
Journal of Clinical Oncology · 2025
DOI: 10.1200/jco-25-00112 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Susana N Banerjee und 24 weiteren Autor:innen. Beteiligte Einrichtung: The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, GTG-UK, London, United Kingdom. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Cystadenocarcinoma, Serous, Neoplasm Recurrence, Local, Ovarian Neoplasms. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
PURPOSE This study evaluated the efficacy and safety of avutometinib (rapidly accelerated fibrosarcoma/mitogen-activated extracellular signal-regulated kinase [MEK] clamp) alone or in combination with defactinib (focal adhesion kinase inhibitor) in patients with recurrent low-grade serous ovarian cancer (LGSOC). METHODS In this phase II, open-label study, patients with recurrent, measurable LGSOC after ≥1 line of platinum chemotherapy were stratified by tumor Kirsten rat sarcoma virus homolog ( KRAS ) mutation status and randomly assigned to oral avutometinib 4.0 mg two times per week monotherapy or avutometinib 3.2 mg two times per week in combination with oral defactinib 200 mg two times per day. The combination was selected as the go-forward regimen for expansion. The primary end point was objective response rate (ORR) by blinded independent central review. RESULTS A total of 115 patients received the go-forward combination regimen. Patients had a median of 3 (range, 1-9) prior lines of therapy, including hormonal (86%), bevacizumab (51%), and MEK inhibitor (22%). Confirmed ORR was 31% (95% CI, 23% to 41%) with a median duration of response of 31.1 months (95% CI, 14.8 to 31.1). ORR was 44% in KRAS- mutant and 17% in KRAS wild-type cohorts. The median progression-free survival was 12.9 months (95% CI, 10.9 to 20.2) overall and 22.0 months (95% CI, 11.1 to 36.6) and 12.8 months (95% CI, 7.4 to 18.4) in KRAS- mutant and wild-type cohorts, respectively. The most frequent grade ≥3 treatment-related adverse events (AEs) were elevated creatine phosphokinase (24%), diarrhea (8%), and anemia (5%). Ten percent of patients discontinued because of AEs. CONCLUSION The efficacy and safety profile of avutometinib in combination with defactinib support this combination as a potential standard of care for recurrent LGSOC. A randomized phase 3 study of avutometinib and defactinib versus investigator's choice of therapy for women with recurrent LGSOC is currently enrolling (RAMP301; ClinicalTrials.gov identifier: NCT06072781 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, GTG-UK, London, United Kingdom.
- University Hospitals Leuven, Leuven Cancer Institute, BGOG, Leuven, Belgium.
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
- Weill Cornell Medical College, New York, NY.
- Institut du Cancer de Montpellier (ICM) Val d'Aurelle Parc Euromedecine, Oncologie Médicale, GINECO, Montpellier, France.
- Florida Cancer Specialists, West Palm Beach, FL.
ORCID-Profile: Susana N Banerjee, Véronique D'Hondt, Bradley J Monk, Emily Prendergast, Ana Oaknin, Nicoletta Colombo, Robert W Holloway, Manuel Rodrigues, Charlie Gourley, Alessandro D Santin, Premal H Thaker, Christine Gennigens, Kathleen N Moore, David M O'Malley, Toon Van Gorp
Förderung
- NCI NIH HHS
Zitieren
APA
Banerjee, S. N., Van Nieuwenhuysen, E., Aghajanian, C., D'Hondt, V., Monk, B. J., Clamp, A., Prendergast, E., Oaknin, A., Ring, K., Colombo, N., Holloway, R. W., Rodrigues, M., Chon, H. S., Gourley, C., Santin, A. D., Thaker, P. H., Gennigens, C., Newman, G., Salinas, E., …, & Grisham, R. N. (2025). Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Journal of Clinical Oncology. https://doi.org/10.1200/jco-25-00112
Vancouver
Banerjee SN, Van Nieuwenhuysen E, Aghajanian C, D'Hondt V, Monk BJ, Clamp A, et al. Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201. Journal of Clinical Oncology. 2025. doi:10.1200/jco-25-00112
BibTeX
@article{Banerjee2025,
author = {Banerjee, Susana N and Van Nieuwenhuysen, Els and Aghajanian, Carol and D'Hondt, Véronique and Monk, Bradley J and Clamp, Andrew and Prendergast, Emily and Oaknin, Ana and Ring, Kari and Colombo, Nicoletta and Holloway, Robert W and Rodrigues, Manuel and Chon, Hye Sook and Gourley, Charlie and Santin, Alessandro D and Thaker, Premal H and Gennigens, Christine and Newman, Gregg and Salinas, Erin and Youssoufian, Hagop and Moore, Kathleen N and Lustgarten, Stephanie and O'Malley, David M and Van Gorp, Toon and Grisham, Rachel N},
title = {Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201},
journal = {Journal of Clinical Oncology},
year = {2025},
doi = {10.1200/jco-25-00112}
}
EUVIMED